Varipulse Bi-Directional Catheter
Biosense Webster, Inc. · Decision date Nov 3, 2026
What did the FDA approve?
FDA records P240006/S018 as a supplement to PMA P240006, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 3, 2026.
FDA approval order statement
extension of the product shelf-life from one (1) year to three (3) years
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 3, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P240006/S018
- Regulatory pathway
- PMA supplement
- Applicant
- Biosense Webster, Inc.
- Product code
- QZI
- Decision code
- APPR
- Decision date
- Nov 3, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Biosense Webster, Inc.
- Product code
- QZI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240006. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240006 · Original PMA
VARIPULSE Platform (VARIPULSE Catheter; TRUPULSE Generator; Sterile Interface Cable; nGEN Pump)
P240006/S018 received
Application receipt date recorded by FDA.
P240006/S019 · Related supplement
VARIPULSE Platform (VARIPULSE Catheter; TRUPULSE Generator; Sterile Interface Cable; nGEN Pump)
P240006/S020 · Related supplement
VARIPULSE BI-DIRECTIONAL CATHETER
P240006/S018 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P240006. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240006
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biosense Webster, Inc. | PMA approval | Nov 6, 2024 | FDA | |
| Biosense Webster, Inc. | PMA supplement | Sep 10, 2026 | FDA | |
VARIPULSE BI-DIRECTIONAL CATHETERP240006/S020 | Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA |
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Globe Catheter and Globe Pulsed Field SystemP240044/S007 | Kardium, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Globe Pulsed Field System; Globe CatheterP240044/S008 | Kardium, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Volt PFA SystemP250022/S002 | ABBOTT MEDICAL | PMA supplement | Oct 15, 2026 | FDA |
Affera Sphere-9 Mapping and Ablation CatheterP240013/S032 | Medtronic, Inc. | PMA supplement | Oct 9, 2026 | FDA |
Volt PFA Catheter, Sensor EnabledP250022/S009 | ABBOTT MEDICAL | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biosense Webster, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 31 Technology Dr., Suite 200, Irvine, CA, 91618
Sources and methodology
- Original FDA record: P240006/S018
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
